Solventum (NYSE:SOLV) Price Target Cut to $48.00 by Analysts at The Goldman Sachs Group

Solventum (NYSE:SOLVGet Free Report) had its price objective cut by equities research analysts at The Goldman Sachs Group from $54.00 to $48.00 in a research report issued on Wednesday, Benzinga reports. The brokerage presently has a “sell” rating on the stock. The Goldman Sachs Group’s price target points to a potential upside of 0.84% from the stock’s current price.

Several other equities analysts have also recently weighed in on SOLV. Edward Jones started coverage on shares of Solventum in a research note on Tuesday, April 2nd. They set a “hold” rating for the company. Argus started coverage on shares of Solventum in a research note on Monday, June 24th. They issued a “hold” rating for the company. Morgan Stanley started coverage on shares of Solventum in a research note on Wednesday, April 10th. They issued an “equal weight” rating and a $70.00 price objective for the company. Wells Fargo & Company started coverage on shares of Solventum in a research note on Monday, April 8th. They issued an “equal weight” rating and a $69.00 price objective for the company. Finally, Bank of America dropped their price objective on shares of Solventum from $70.00 to $60.00 and set a “neutral” rating for the company in a research note on Tuesday, June 25th. One research analyst has rated the stock with a sell rating and five have assigned a hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $61.75.

View Our Latest Stock Report on SOLV

Solventum Stock Performance

Shares of NYSE SOLV traded down $0.42 during midday trading on Wednesday, reaching $47.60. The stock had a trading volume of 342,129 shares, compared to its average volume of 2,367,632. The business’s 50-day simple moving average is $57.46. Solventum has a 12-month low of $47.35 and a 12-month high of $96.05. The company has a debt-to-equity ratio of 2.16, a current ratio of 1.81 and a quick ratio of 1.33.

Solventum (NYSE:SOLVGet Free Report) last posted its earnings results on Thursday, May 9th. The company reported $2.08 earnings per share for the quarter, beating the consensus estimate of $1.67 by $0.41. The company had revenue of $2.02 billion for the quarter, compared to analysts’ expectations of $1.99 billion. Equities analysts anticipate that Solventum will post 6.23 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Solventum

Institutional investors have recently made changes to their positions in the company. Partnership Wealth Management LLC bought a new stake in shares of Solventum in the 2nd quarter worth about $26,000. M&R Capital Management Inc. bought a new stake in Solventum during the 2nd quarter valued at about $27,000. Beach Investment Counsel Inc. PA bought a new stake in Solventum during the 2nd quarter valued at about $27,000. S.A. Mason LLC bought a new stake in Solventum during the 2nd quarter valued at about $29,000. Finally, Thurston Springer Miller Herd & Titak Inc. bought a new stake in Solventum during the 2nd quarter valued at about $29,000.

Solventum Company Profile

(Get Free Report)

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.

Read More

Analyst Recommendations for Solventum (NYSE:SOLV)

Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.